Platinum is a key component of ovarian cancer systemic therapy. However, most patients will eventually face a recurrence, leading to chemotherapy resistance, especially against platinum. For individuals with platinum-resistant ovarian cancer (PROC), treatment options are limited, and their survival ...
Platinum is a key component of ovarian cancer systemic therapy. However, most patients will eventually face a recurrence, leading to chemotherapy resistance, especially against platinum. For individuals with platinum-resistant ovarian cancer (PROC), treatment options are limited, and their survival prospe...
Tolerable in Advanced Gastric/GEJ Cancer First-Line Nivolumab/Chemo Generates Long-Term Survival Benefits in Gastric/GEJ/Esophageal Cancer Evorpacept Plus TRP Generates Superior Antitumor Responses, Survival Outcomes in HER2+ Gastric/GEJ Cancer
Ovarian cancer is a prevalent gynecologic malignancy with the second-highest mortality rate among gynecologic malignancies. Platinum-based chemotherapy is the first-line treatment for ovarian cancer; however, a majority of patients with ovarian cancer experience relapse and develop platinum resistance followi...
Ex vivo generation of CD3-positive, CD56-positive Natural Killer-Like (NKT) with CRX100 was successful in all 7 patients with ovarian cancer in a phase 1 trial.
www.nature.com/scientificreports OPEN AKR1C1/2 inhibition by MPA sensitizes platinum resistant ovarian cancer towards carboplatin Susann Badmann1, Doris Mayr2, Elisa Schmoeckel2, Anna Hester1, Christina Buschmann1, Susanne Beyer1, Thomas Kolben1, Fabian Kraus1, Anca ...
The objective was to determine the response rate to platinum retreatment of "platinum-resistant" ovarian cancer after intervening nonplatinum therapy. We retrospectively identified 30 patients with platinum-resistant ovarian cancer who received nonplatinum chemotherapy for recurrent epithelial ovarian cancer pr...
Luveltamab tazevibulin produced responses in patients with platinum-resistant ovarian cancer. Ovarian Cancer_Dr Microbe - stock.adobe.com Treatment with the folate receptor alpha (FRα)–targeted antibody-drug conjugate (ADC) luveltamab tazevibulin (luvelta; STRO-002) led to...
Weekly topotecan is a well-tolerated and effective regimen for platinum-resistant ovarian cancer with considerable less hematological toxicity when compared with historical data for the 5-day regimen.doi:10.1016/j.ygyno.2007.08.062Fadi Abushahin
This case report supports the prospective evaluation of alternative therapies such as these in patients with platinum-refractory ovarian cancer. 展开 关键词: Ovarian cancer Platinum-resistance Alternative therapies Genistein DOI: 10.1016/j.ygyno.2005.08.006 被引量: 37 ...